GlassScriptPhysician profile
Sandra Amoils
NPI 1265495055
$450.86
in general payments reported to CMS, 2019-2025
11 companies · $68.01 in 2025
The $68.01 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.30 · 2021: $30.80 · 2022: $77.31 · 2023: $61.64 · 2024: $123 · 2025: $68.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $252.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.11 | 2019-2021 | |
| Abbvie INC. | $80.47 | 2022-2025 | Qulipta |
| Novo Nordisk INC | $55.15 | 2022-2024 | Wegovy |
| Amgen INC. | $44.62 | 2024 | Repatha |
| Abbott Laboratories | $40.27 | 2022-2023 | Freestyle Libre 2 |
| Exact Sciences Corporation | $29.31 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $25.83 | 2024 | Voquezna |
| Lilly USA, LLC | $19.05 | 2025 | Zepbound, Mounjaro |
| Itamar Medical INC | $18.86 | 2024 | Watchpatone |
| Astrazeneca Pharmaceuticals LP | $16.20 | 2024 | Airsupra |
| Biohaven Pharmaceuticals, INC. | $15.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Amoils listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.